Expression of E-Cadherin/Beta-Catenin in Epithelial Carcinomas of the Thyroid Gland

Koni Ivanova; Julian Ananiev; Elina Aleksandrova; Maria Magdalena Ignatova; Maya Gulubova

doi:10.3889/oamjms.2017.043

Authors

Koni Ivanova Medical Faculty, Trakia University, General and Clinical Pathology, Stara Zagora
Julian Ananiev Medical Faculty, Trakia University, General and Clinical Pathology, Stara Zagora
Elina Aleksandrova Medical Faculty, Trakia University, General and Clinical Pathology, Stara Zagora
Maria Magdalena Ignatova Medical Faculty, Trakia University, General and Clinical Pathology, Stara Zagora
Maya Gulubova Medical Faculty, Trakia University, General and Clinical Pathology, Stara Zagora

DOI:

https://doi.org/10.3889/oamjms.2017.043

Keywords:

E-cadherin, Î²-catenin, thyroid cancer, survival, tumorogenesis

Abstract

BACKGROUND: The aberrant activation of Wnt signalling pathway may be a common denominator for the development of thyroid tumorigenesis. It was announced that the loss of E-cadherin rather than Î²-catenin mutation represents a crucial event in determining the degree of differentiation of thyroid carcinomas.

AIM: The aim of the study was to evaluate the expression of E-cadherin and Î²-catenin in the thyroid cancer tissue and to correlate these data with some histological and clinical parameters of the tumours.

MATERIAL AND METHODS: We investigated 112 patients, having thyroid tumours â€“ papillary, follicular, anaplastic and oncocytic carcinomas immunohistochemically with antibodies against E-cadherin and Î²-catenin. Survival analyses were done.

RESULTS: E-cadherin expression was focally retained in the tumour cell membranes and the tumour cell cytoplasm of the papillary, follicular and oncocytic thyroid cancers, weather in anaplastic cancers it was almost lost (p = 0.0042, and Ñ€ = 0.019, respectively, Fisher's Exact Test). The expression of Î²-catenin in tumour cytoplasm and membrane in papillary cancers was higher as compared to that in the other tumours (p = 0.111, and Ñ€ = 0.0104, respectively).

CONCLUSION: Not surprisingly, the presence of aberrant expression of E-cadherin and Î²-catenin in thyroid cancer has been associated with better patients' prognosis and better differentiated tumour histology.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Takano T. Fetal cell carcinogenesis of the thyroid. Endocrine journal. 2004;51(6)509-515. https://doi.org/10.1507/endocrj.51.509 PMid:15644567

Ito Y, Miyauci A. Prognostic factors and therapeutic strategies for diferentiated carcinomas of the thiroid. Endocr J. 2009;56177-192.

Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, et al. Abberant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab. 2002;87:3433-3440. PMid:12107263

Van Aken E, De Wever O, da Rocha ASC, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 2001;439:725-751. https://doi.org/10.1007/s004280100516 PMid:11787845

Brabletz T, Jung A, Kirchner T. Î²-Catenin and the morphogenesis of colorectal canvcer. Virchows Arch. 2002;441:1-11. https://doi.org/10.1007/s00428-002-0642-9 PMid:12111194

Barabant G at al. E-cadherin a differentiation marker in thyroid malignancies. Cancer Res. 1993;135:575-581.

Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 2003;94(7):575-581. https://doi.org/10.1111/j.1349-7006.2003.tb01485.x PMid:12841864

Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surgery. 2006;191:581-587. https://doi.org/10.1016/j.amjsurg.2006.02.005 PMid:16647341

Erdem H, Gundogdu C, Sipal S. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011;90:312-317. https://doi.org/10.1016/j.yexmp.2011.01.008 PMid:21335003

Rocha AS, Soares P, Fonseca E, et al. E-cadherin loss rather than beta-catenin alterations is acommon feature of poorly differentiated thyroid carcinomas. Histopathology. 2003;42:580-587. https://doi.org/10.1046/j.1365-2559.2003.01642.x PMid:12786894

Garcia-Rostan G, Robert L, David L, Giovanni T. Î²-catenin Dysregulation in thyroid neoplasms down-regulation, aberrant nuclear expression, and CTNNB1 Exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. American journal of pathology. 2001;158(3)987-996. https://doi.org/10.1016/S0002-9440(10)64045-X

Yap AS. The morphogenetic role of cadherin cell adhesion molecules in human cancer: a thematic review. Cancer Invest. 1998;16(4):252-261. https://doi.org/10.3109/07357909809039774 PMid:9589034

Rocha AS, Smit DI, Thibodeau SN . Frequent mutation and nuclear localization of E-cadherin in anaplastic thyroid carcinoma. Cancer Res. 2000;26:146-147.

El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008;3:5. https://doi.org/10.1186/1746-1596-3-5 PMid:18254952 PMCid:PMC2267445

Kapran Y, Ozbey N, Molvalilar S, Snecer E, Disdalogru F, Ozarmagan S. Immunohistochemical detection of E-cadherin alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest. 2002;25:578-585. https://doi.org/10.1007/BF03345079 PMid:12150330

Guarino V, Castellone MD, Avila E, Rosa MM. Thyroid cancer and inflammation. Molecular and cellular Endocrinology. 2010;321:94-102. https://doi.org/10.1016/j.mce.2009.10.003 PMid:19835928

Gilbert-Sirieix M, Makoukji J, Kimura S, Talbot M, Caillou B, Massaad C, Massaad-Massade L. Wnt/Î²-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells. Plos one. 2011;6(7): e22280. https://doi.org/10.1371/journal.pone.0022280 PMid:21814573 PMCid:PMC3141030

P. Soares, G. Berx, F.V Roy, M. Sobrinho-SimÃµes. E-cadherin gene alteration are rare events in thyroid tumors. Int J Cancer. 1997;70:32-38. https://doi.org/10.1002/(SICI)1097-0215(19970106)70:1<32::AID-IJC5>3.0.CO;2-7

Batistatou A, Konstantinos C, Yukihiro N, Constantine V, Setsuo H, Niki JA, Chrissoula DS. Differential Expression of Dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol. 2008;19:197-202. https://doi.org/10.1007/s12022-008-9035-1 PMid:18677652

Fluimara A, Russo G, Salomone E et al. In situ evidence of neoplastic cells phagocytes by macrophages in papillary thyroid cancer. Clin Endocrinol Metab. 1997;82:1615-1620.

Mantovani A, Schippa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast Rev. 2006;25:315-322. https://doi.org/10.1007/s10555-006-9001-7 PMid:16967326

Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA. Increased density of tumor -associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15(4):1069-1074. https://doi.org/10.1677/ERC-08-0036 PMid:18719091 PMCid:PMC2648614

Underwood JCE. Lymphoreticular infiltration in human tumors. Br J Cancer.1974;30:538-548. https://doi.org/10.1038/bjc.1974.233 PMid:4614858 PMCid:PMC2009334

Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenviroments. Cancer Research. 2006;66:605-612. https://doi.org/10.1158/0008-5472.CAN-05-4005 PMid:16423985